Displaying drugs 14626 - 14650 of 15807 in total
CypCaps
Investigational
Myb34.5
Investigational
Albumin-stabilized nanoparticle (130 nm)
Investigational
Boserolimab
Investigational
CD8+ enriched young tumor infiltrating lymphocytes
Investigational
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
CD-16 NK-92 cells
Investigational
LP-2307
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
APL-502
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
Autogene cevumeran
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
Investigational
Batiraxcept
Investigational
ETBX-051
Investigational
GCS-100
Investigational
Crefmirlimab
Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.
Investigational
PEG-interleukin-2
Investigational
RP-L201
Investigational
OCE-205
Investigational
TAK-611
TAK-611, formerly known as SHP611, is a recombinant human arylsulfatase A. First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.
Investigational
PEG-Glucocerebrosidase
Investigational
rAAV9-rsATP7A
A recombinant adeno-associated viral vector gene therapy under investigation for the treatment of Menkes disease.
Investigational
mRNA-3705
mRNA-3705 is an investigational mRNA encoding methylmalonic CoA mutase (MUT) enzyme. Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.
Investigational
Recombinant human alkaline phosphatase
Investigational
LV-FAH
Investigational
NZ-1002
Investigational
Displaying drugs 14626 - 14650 of 15807 in total